Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG – Get Free Report) shares dropped 4.8% during mid-day trading on Monday . Zacks Research raised shares of Hemab Therapeutics to a “hold” rating in a research report on Wednesday, May 27th. Get Hemab Therapeutics alerts:View Our Latest Stock Analysis on COAGHemab Therapeutics Stock Up 3.2%The company has a 50 day simple moving average of $35.19. Hemab Therapeutics (NASDAQ:COAG – Get Free Report) last posted its quarterly earnings data on Thursday, May 21st. Hemab Therapeutics Company Profile(Get Free Report)Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders.